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R ECENTLY, it has been demonstrated that the proin-flammatory cytokines such as tumor necrosis factor 
(TNF) and interleukin (IL)-1 may play an important role in 
ischemia-reperfusion (I-R) injury in several organs such as 
the liver. lung, kidney, heart, and small intestine, both in 
nontransplant and in transplant experimental models,1,2 as 
well as in clinical transplant cases.3 A newly developed 
agent, FR167653 (FR), has recently been shown to have 
potent specific inhibitory effects on TNF-a and IL-li3 
activity in vitro and in vivo. In this study, we investigated the 
protective effect of FR on I-R injury of intestinal grafts as 
well as remote organs such as liver, kidney, and lung in a rat 
transplantation model. 
MATERIALS AND METHODS 
Syngeneic orthotopic small intestinal transplantation (SIT) was 
performed using Lewis rats, in which the graft was preserved for 12 
hours in cold (4°C) lactated Ringer's solution. FR was administered 
to the recipients intravenously for 4 hours starting at 30 minutes 
prior to repertusion, at the dose of 0.25 mg/kg per hour (FR 
group), or vehicle (saline) only (control group). Animal survival, 
histology of small intestinal graft, plasma levels of TNF-a and 
IL-1(:l, plasma GPT and creatinine, tissue myeloperoxidase (MPO) 
activity, as well as neutrophil infiltration in lung, were compared. 
RESULTS 
Eleven of 14 animals in the FR group survived over 48 
hours after transplantation, whereas only 5 animals survived 
in the control group (P < .05). There was no difference in 
the grading score of intestinal graft injury between the 
groups. Plasma level of TNF-a in the FR group was 
significantly suppressed at 12 hours after reperfusion com-
pared to the control group (56.6 ::': 39.6 versus 101.8 ± 34.2 
pglmL), whereas that of IL-li3 was significantly suppressed 




control group (12.2 ± 5.9 versus 18.9 ± 15.0 pglmL, P < 
.05). There was no difference in plasma OPT levels between 
the groups, whereas plasma creatinine level in the FR group 
was significantly improved at 4 and 12 hours after reperfu-
sion compared to the control group (1.00 ± 0.09 versus 
1.13 ± 0.08 mgldL at 4 hours, P < .05; 0.88 ± .31 versus 
1.45 ± 0.51 mgldL at 12 hours, P < .01, respectively). Tissue 
MPO activity in the lung at 12 hours after reperfusion was 
significantly suppressed in the FR group compared to the 
control group (0.31 ± 0.08 versus 0.41 ± 0.10 .:lOD4w'min 
per g, P < .05), whereas neutrophil infiltration in the lung 
at 12 hours after reperfusion was significantly lower in the 
FR group compared to the control group (37.2 ± 7.7 versus 
46.6 ± 8.3 in 10 HPF, P < .05). 
CONCLUSION 
In rat small intestinal transplantation, not the graft itself but 
the remote organs such as lung and kidney are the critical 
organs for ischemia-reperfusion injury. TNF-a and IL-1i3 
are thought to be important mediators of ischemia-reper-
fusion related remote organ injury in lung and kidney. 
FR167653 is an effective drug to prevent the ischemia-
reperfusion-related remote organ injury in rat small intes-
tinal transplantation. 
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